Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
- Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo - - Unique broad mechanistic effect across...
Restart Life Closes Over-Subscribed Second Tranche Financing